Table 2 Fidaxomicin utilization stratified by CDI episodes
From: A multi-center study of fidaxomicin use for Clostridium difficile infection
Early episodes | Later episodes | Overall (n = 102) | |||
|---|---|---|---|---|---|
Episode 1 (n = 37) | Episode 2 (n = 32) | Total (n = 69) | Episode ≥ 3 (n = 33) | ||
Mild-moderate CDI; n(%) | 10 (27 %) | 12 (37.5 %) | 22 (32 %) | Not applicable | 22/69 (32 %) |
Severe CDI; n(%) | 27 (73 %) | 20 (62.5 %) | 47 (68 %) | Not applicable | 47/69 (68 %) |
1. FDX monotherapy; n (%) | 3 (8 %) | 4 (12.5 %)a | 7 (10 %) | 6 (18 %) | 13 (13 %) |
2. Other CDI therapy; n (%) | 34 (92 %) | 27 (84 %) | 61 (88 %) | 27 (82 %) | 88 (86 %) |
I. Subsequent; n | 18 | 14 | 32 | 16 | 48 |
II. Subsequent and combination; n | 8 | 6 | 14 | 2 | 16 |
III. Combination; n | 2 | 1 | 3 | 1 | 4 |
IV. Unable to categorize; n | 6 | 6 | 12 | 8 | 20 |
Concomitant non-CDI antibiotics; n (%) | 25 (68 %) | 10 (31 %) | 35 (51 %) | 13 (39 %) | 48 (47 %) |